Segmentation in non-small-cell lung tumors using 18F-fluorodeoxyglucose PET/CT: tips and rules.
2020 - GA Jiménez Londoño, J. Pérez-beteta, Jesús J. Bosque, Antonio F. Hoguero, Ana M García Vicente
Clinical Nuclear Medicine (in press)
The assessment of tumor parameters derived from 18 F-fluorodeoxyglucose-positron emission tomography/computed tomography ( 18 F-FDG-PET/CT) in oncology provides valuable information in non-small-cell lung cancer (NSCLC). A proper segmentation should delineate tumor with high accuracy, being the most important step to measure metabolic parameters. However, there is still no consensus about the optimal methodology. Additionally, some clinical conditions inherently tied to tumor and imaging can limit the proper tumor delineation. We present some practical cases that represent different aspects to consider during segmentation of primary NSCLC by using 18 F-FDG-PET/CT and some possible solutions to tackle with the most common limitations in clinical practice.